-55%

est. 2Y upside i

HealthcareSeries B

We make healthcare in emerging markets affordable and accessible

Rank

#917

Sector

HealthTech

Est. Liquidity

~4Y

Data Quality

Data: Medium

Reliance Health presents a moderate upside opportunity, driven by its high historical growth and integrated model in a large emerging market.

Last updated: March 10, 2026

Bull (25%)+300%

Reliance Health successfully expands into new emerging markets and significantly scales its integrated platform, achieving sustained profitability. This drives revenue to over $300M by 2028 and justifies an $800M valuation, reflecting strong market leadership and execution in a high-growth sector.

Base (45%)+75%

Reliance Health maintains its competitive position in existing markets, achieving moderate growth and nearing breakeven. Revenue reaches approximately $150M by 2028, leading to a $350M valuation as the company demonstrates a viable, albeit slower, path to profitability and market penetration.

Bear (30%)-60%

Increased competition and regulatory hurdles in emerging markets, coupled with a failure to achieve sustainable profitability post-layoffs, lead to stalled growth and a down round. The company's valuation drops to $80M, significantly eroding common stock value due to existing liquidation preferences.

Est. time to liquidity~4.0 years

Preference Stack Risk

high

Investors hold $48M in liquidation preferences, meaning common stock holders would only see returns after this amount is paid out in an exit.

Dilution Risk

high

As a Series B company not yet profitable, additional funding rounds are highly probable, which will lead to further dilution of existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Reliance Health equity.

Questions to Ask at the Interview

Strategic questions based on Reliance Health's data — designed to show you've done your homework.

  • 1

    “Given the recent layoffs, how is Reliance Health ensuring it can sustain its historical growth rates while also achieving profitability in the next 12-24 months?”

  • 2

    “With a moderate competitive moat and medium incumbent threat, what specific strategies are in place to differentiate Reliance Health from both traditional HMOs like Hygeia and AXA Mansard, and other digital health platforms like Mobihealth, especially as they expand their offerings?”

  • 3

    “Considering the Series B funding and the aim for breakeven, what is the anticipated timeline for a liquidity event (IPO or acquisition), and how does the company plan to manage potential dilution for employees in future funding rounds?”

Community

Valuation Sentiment

Our model estimates -55% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.